BioSpace News Archive

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million.

Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs” or “Company”) today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other malignant tumors, has been approved by the FDA (U.S. Food and Drug Administration).

In underserved and under-resourced communities across the globe, from the U.S. to Rwanda, our company is helping patients at risk for and living with cancer access the care they need to stay well and lead fulfilling lives.

Navidea Biopharmaceuticals, Inc. announced that on June 14, 2023 it entered into an amendment to the Asset Purchase Agreement, dated November 23, 2016, between the Company and Cardinal Health 414, LLC, an affiliate of Cardinal Health, Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition.

Lannett Company, Inc. announced that it and certain of its subsidiaries have successfully emerged from their Chapter 11 cases following the confirmation of its Plan of Reorganization on June 8, 2023.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that the U.S. Food and Drug Administration (FDA) has approved its application for premarket approval (PMA) of its RECELL® System for the treatment of vitiligo.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting.

The International Niemann-Pick Disease Registry (INPDR) and biopharmaceutical company Mandos Health today announce a new collaboration giving Mandos Health controlled access to registry information via INPDR’s research “Gateway” platform.